AstraZeneca Crestor NDA Includes Rhabdomyolysis Reports At Highest Dose

AstraZeneca's discussions with FDA about the safety profile of the experimental cholesterol drug Crestor (rosuvastatin) are focusing on the potential for the highest dose to cause rhabdomyolysis, the company indicated during analysts meetings the week of Dec. 3